Research Topics
| Katrien PrincenSummaryAffiliation: Katholieke Universiteit Leuven Country: Belgium Publications
|
Detail Information
Publications
HIV chemokine receptor inhibitors as novel anti-HIV drugsKatrien Princen
Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Cytokine Growth Factor Rev 16:659-77. 2005..Both CXCR4 and CCR5 chemokine receptor inhibitors will be needed in combination and even in combinations of antiviral drugs that also target other aspects of the HIV replication cycle to obtain optimum antiviral therapeutic effects...- Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonistsKatrien Princen
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
Retrovirology 1:2. 2004..Here, we describe the establishment of a novel CD4+ cell line, U87.CD4.CCR5.CXCR4, stably expressing both CCR5 and CXCR4 at the cell surface... - The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression levelKatrien Princen
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Department of Virology and Chemotherapy, Ninderbroedersstraat 10, B 3000 Leuven, Belgium
AIDS Res Hum Retroviruses 19:1135-9. 2003..Our data indicate that CXCR4 antagonists such as AMD3100 act independently of the HIV-1 coreceptor expression level. These compounds should therefore be useful in suppressing HIV-1 infection in all stages of the disease... - Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometryKatrien Princen
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Cytometry A 51:35-45. 2003..Both assay systems were compared for their sensitivity, advantages, and system-dependent limitations... - Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonistKatrien Princen
Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium
J Virol 78:12996-3006. 2004..AMD3451 is the first low-molecular-weight anti-HIV agent with selective HIV coreceptor, CCR5 and CXCR4, interaction... - CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitroKurt Vermeire
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
AIDS 18:2115-25. 2004..To evaluate the anti-HIV-1 activity of the cyclotriazadisulfonamide CADA against primary isolates in vitro and the combination of CADA with approved anti-HIV drugs for potential synergy... - Modest human immunodeficiency virus coreceptor function of CXCR3 is strongly enhanced by mimicking the CXCR4 ligand binding pocket in the CXCR3 receptorSigrid Hatse
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
J Virol 81:3632-9. 2007..Moreover, the CXCR4 antagonist AMD3100 exhibited antagonistic and anti-HIV activities in U87.CD4.CXCR3[K300A, S304E] cells but not in U87.CD4.CXCR3[WT] cells... - Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studiesSigrid Hatse
Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Cytometry A 61:178-88. 2004..Therefore, potent and specific CXCR4 antagonists may have therapeutic potential as anti-HIV, anti-cancer, and anti-inflammatory drugs... - The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivityDana Huskens
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Virology 363:280-7. 2007..Since CXCR4 N-glycans play a less important role in viral entry compared to the N-glycans on the HIV envelope, cells expressing CXCR4 N-glycosylation mutants might be no relevant alternative to allow HIV-1 escape from antivirals... - AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitorSigrid Hatse
Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Biochem Pharmacol 70:752-61. 2005.... - Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entrySigrid Hatse
Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
FEBS Lett 546:300-6. 2003..3. Thus, resistance of HIV-1 NL4.3 to AMD3100 is associated with a decreased dependence of the viral gp120 on Asp(262) of CXCR4, pointing to a different mode of interaction of wild-type versus AMD3100-resistant virus with CXCR4... - Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4Sigrid Hatse
Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000, Leuven, Belgium
FEBS Lett 527:255-62. 2002..g. rheumatoid arthritis, atherosclerosis, asthma and breast cancer metastasis)... - Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infectionJan Balzarini
Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Antimicrob Agents Chemother 48:3858-70. 2004..0) for prolonged time periods and can be easily formulated in gel preparations for microbicidal use; they did not agglutinate human erythrocytes and were not toxic to mice when administered intravenously... - CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptorKurt Vermeire
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
Virology 302:342-53. 2002..This unique mechanism of action makes CADA an important lead in developing new drugs for treatment of AIDS, autoimmune diseases, and inflammatory disorders...